Desentum

News

Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen 2022 / Summons to the 2022 Annual General Meeting of Desentum Oy

03.06.2022

Desentum Oy:n varsinainen yhtiökokous pidetään 22.6.2022 / The AGM of Desentum Oy is to be held on Jun 22nd, 2022.

Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate

21.01.2022

Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros...

Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

25.10.2021

Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen...

Show all »

DESENTUM

Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.

TECHNOLOGY

Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.

Imagine a world without allergies.

News

DESENTUM

TECHNOLOGY

Join our mailing list